Home page > News and Press-release

Authorize the processing of personal data
Edit email address
Invalid email
Email Sent
Authorize the processing of personal data
Chiesi and Gossamer Bio Announce Transformative Global Collaboration to Develop...
Strategic collaboration to leverage Chiesi's legacy of respiratory leadership and Gossamer Bio's development expertise in pulmonary hypertension. Gossamer to receive $160 million development...
Alessandro Chiesi appointed Chair of the Chiesi Group Maria Paola Chiesi becomes the Vice Chair
2022 for Chiesi: The Group’s international growth continues
Chiesi Group and Affibody collaborate to develop and commercialize innovative treatments for respiratory diseases
What does it mean to be a B Corp? Chiesi's choice for a sustainable future
Chiesi appoints Giuseppe Accogli as new Group CEO
Chiesi is recertified as a B Corp and sets new tougher objectives for action by 2025
Chiesi tracks actions taken for a healthier, more sustainable future
Chiesi accelerates path toward full sustainability despite Covid-19 pandemic
Chiesi Group calls for #ActionOverWords in the fight against climate change
New organisational order for the Chiesi Foundation
Chiesi Group receives European Marketing Authorisation for Trimbow® (beclometasone/formoterol/glycopyrronium) NEXThaler, an extrafine formulation fixed triple combination therapy for the treatment of moderate to severe COPD.
Chiesi continues cultural transformation with new visual identity that mirrors patients’ language and experiences
Chiesi Group receives the European Marketing authorisation for the extrafine triple-combination therapy for the treatment of moderate to severe asthma
Chiesi publishes its annual report: Group generates almost €2 billion and obtains B Corp certification in 2019
Chiesi Group increases support measures and announces new funds for employees, patients and healthcare providers in response to COVID-19 pandemic
Chiesi Group Announces Establishment of New Global Rare Diseases Division
Chiesi outlines €350 million investment and announces first carbon minimal pressurised Metered Dose Inhaler (pMDI) for Asthma and COPD
We ACT Day 2019: Chiesi sets itself the challenge of becoming carbon neutral by 2035
Chiesi Group Announces Closing of Licensing Transaction with Santhera for an orphan drug in LHON
Chiesi Group is the largest pharmaceutical group in the world to be awarded B Corp certification
Chiesi and Holostem Announce FDA Orphan Drug Designation for GPLSCD01 for treatment of Limbal Stem Cell Deficiency (LSCD)
Chiesi Group receives the European Marketing Authorisation for Lamzede®▼(velmanase alfa)
TRIBUTE study shows superiority of Chiesi’s Trimbow® (Beclometasone dipropionate (BDP), Formoterol fumarate (FF) and Glycopyrronium (GB)) over Ultibro® (indacaterol/glycopyrronium) in reducing COPD exacerbations1
Chiesi Group receives the European Marketing Authorisation for Trimbow® (inhaled corticosteroid / long-acting β2-agonist / long-acting muscarinic antagonist)
Trimbow® is the first triple combination in a single inhaler for the treatment of COPD to receive positive opinion from the CHMP in Europe
Chiesi Group reports an increased turnover in 2016 and consolidates its global presence
Glybera▼ (alipogene tiparvovec) in Europe
For the second time, Chiesi’s extrafine fixed dose ICS/LABA/LAMA triple therapy earns a place in the pages of The Lancet, with the publication of Chiesi’s TRINITY study.
GOLD 2017 Report: Chiesi Farmaceutici highlights relevant gaps
Chiesi Enhances Asthma Portfolio with Acquisition of Atopix Therapeutics
The Italian Prime Minister Matteo Renzi, has visited Chiesi Farmaceutici Research Center in Parma